Deutsche Bank Aktiengesellschaft Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $12.00

Key Points

• Deutsche Bank Aktiengesellschaft raised Sarepta Therapeutics' price target from $6.00 to $12.00, maintaining a "sell" rating, indicating a potential downside of 44.74% from the current price.
• Sarepta Therapeutics reported $2.02 EPS and $611.09 million in revenue for the last quarter, significantly exceeding analyst estimates, though the company still has a negative net margin of 2.34%.
• Institutional investors own 86.68% of Sarepta Therapeutics' stock, highlighting strong institutional interest despite the mixed ratings from analysts, with six citing "sell" ratings.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target increased by equities researchers at Deutsche Bank Aktiengesellschaft to $12.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a "sell" rating on the biotechnology company's stock. Deutsche Bank Aktiengesellschaft's target price indicates a potential downside of 44.98% from the stock's current price.

Other research analysts have also issued reports about the company. Jefferies Financial Group lowered their price target on Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating for the company in a research report on Thursday, July 24th. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. Oppenheimer upgraded Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $30.00 to $37.00 in a research report on Tuesday, July 29th. Guggenheim cut their target price on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Wolfe Research began coverage on Sarepta Therapeutics in a research report on Tuesday, June 17th. They set a "peer perform" rating on the stock. Six equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $43.63.

Sarepta Therapeutics Stock Up 7.4%

Shares of SRPT traded up $1.51 during trading hours on Friday, hitting $21.81. The company had a trading volume of 8,824,998 shares, compared to its average volume of 6,138,288. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $144.22. The company's fifty day moving average price is $20.17 and its two-hundred day moving average price is $54.62. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $2.13 billion, a PE ratio of -25.07 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%. The company had revenue of $611.09 million during the quarter, compared to analysts' expectations of $530.66 million. During the same quarter in the prior year, the firm posted $0.07 EPS. Sarepta Therapeutics's quarterly revenue was up 68.4% compared to the same quarter last year. As a group, equities analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Byrne Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics in the 1st quarter worth about $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth about $31,000. Ancora Advisors LLC lifted its stake in Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 300 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth approximately $44,000. Finally, Pandora Wealth Inc. acquired a new stake in Sarepta Therapeutics during the 1st quarter worth $45,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.